Bispecific antibody · developed by Immatics Biotechnologies GmbH
IMA402 is administered by intravenous infusion, alone or together with IMA401, and has been studied in patients with refractory, recurrent or solid tumor cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05958121 | Phase 1/2 | Refractory Cancer | Recruiting | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerRecurrent CancerRefractory CancerSolid Tumor, Adult
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →